Blood Cancer: A Study of APTO-253 in Patients With Acute Myelogenous Leukemia (AML)
or Myelodysplastic Syndrom (MDS)
Research Question:
What is the safety and effectiveness of APTO-253 for the treatment of patients with
the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)
for which either the standard treatment has failed, is no longer effective, or can
no longer be administered safely or poses a risk for your general well being?
Basic Study Information
Purpose:
This study is being done to evaluate the safety and effectiveness of APTO-253 for
the treatment of patients with the condition of acute myelogenous leukemia (AML) or
myelodysplastic syndrome (MDS) for which either the standard treatment has failed,
is no longer effective, or can no longer be administered safely or poses a risk for
your general well being.
Location: University of Rochester Medical Center
Study Reference #: ILEU18011
Lead Researcher (Principal Investigator)
Lead Researcher:
Kristen O'Dwyer
Study Contact Information
Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search